Home
Inozyme

Inozyme Market Share Analysis for May 2026

European laws, including the General Data Protection Regulation (“GDPR”) and the e-Privacy Directive 2002/58/EC, create obligations for digital publishers such as Inozyme Pharma (“Inozyme”) to give visitors of their sites and apps information about how they will use and share their personal data, as well as about the use of cookies, mobile ad IDs, and […]

Industry: N/A

Domaininozyme.com

Year Founded2015

Employees51 - 200

Annual Revenue$10M - $15M

Inozyme

Inozyme (including company regionals)

inozyme.com

See more website traffic and engagement information

Inozyme Revenue up to May 2026 is 10M - 15M

revenue generated by Inozyme top domains

Inozyme top domains revenue over 3 years

Revenue for Inozyme top domains

inozyme.com10M - 15M

See more with Sales Intelligence

Total visits to Inozyme's top domains

Understand Inozyme market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

inozyme.com940

See more with Sales Intelligence

Avg. visit duration in Inozyme's top domains

Analyze Inozyme engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

inozyme.com--

See more with Sales Intelligence

Avg. pageviews on Inozyme's top domains

See how Inozyme keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

inozyme.com1.07

See more with Sales Intelligence

Inozyme top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Inozyme

These are the website technologies, by industry, used by Inozyme top domains

Widget (5)

Twemoji

Audio Video Media (3)

YouTube

Content Management System (3)

WordPress

Advertising (2)

DoubleClick

More Technologies

10

See all

News & Signals from Inozyme

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsDuda leaves Inozyme Pharma, Inc. as Chief Medical Officer.Prior to joining GlycoEra, Dr. Duda served as Chief Medical Officer at Inozyme Pharma in Boston, MA, where she oversaw a clinical portfolio focused on rare and ultra-rare diseases and helped guide programs through key stages of development.

NewsInozyme Pharma, Inc. launches JBMR Plus publication demonstrating real-world impact of ENPP1 Deficiency.Inozyme Pharma announces JBMR Plus publication demonstrating real-world impact of ENPP1 Deficiency.

NewsInozyme Pharma, Inc. attends event 24th Annual Needham Virtual Healthcare Conference.Inozyme Pharma to participate in the 24th Annual Needham Virtual Healthcare Conference.